How Vaccines Work: The Science of Immunization

The Principle Behind Vaccination

Vaccination works by exploiting the adaptive immune system's ability to remember previous encounters with pathogens. When the body encounters a pathogen for the first time, the adaptive immune system mounts a primary response that takes days to weeks to develop. During this time, the pathogen may cause disease. If the same pathogen is encountered again, however, memory B cells and memory T cells generated during the first encounter can mount a secondary response that is faster, stronger, and more effective, often eliminating the pathogen before it can cause symptoms.

A vaccine mimics a natural infection without the associated disease risk. It presents the immune system with antigens, molecular structures from the pathogen that the immune system can recognize and respond to. The immune system reacts to these antigens just as it would to a real infection, producing antibodies, activating T cells, and generating memory cells. When the vaccinated person later encounters the actual pathogen, the pre-existing immunological memory enables a rapid, effective response that prevents or greatly reduces the severity of disease.

Types of Vaccines

Several different approaches are used to create vaccines, each with its own advantages and limitations. Live attenuated vaccines contain weakened forms of the pathogen that can replicate in the body but are too weak to cause disease in healthy individuals. Because they closely mimic natural infection, live attenuated vaccines typically produce strong, long-lasting immunity, often with just one or two doses. Examples include the measles-mumps-rubella (MMR) vaccine, the varicella (chickenpox) vaccine, and the oral polio vaccine. The main disadvantage is that they cannot be given to immunocompromised individuals, in whom even the weakened pathogen might cause disease.

Inactivated vaccines contain pathogens that have been killed by heat, chemicals, or radiation and can no longer replicate. They are safer than live vaccines for immunocompromised individuals but generally produce weaker immune responses and often require multiple doses or booster shots to maintain immunity. Examples include the inactivated polio vaccine (IPV), the hepatitis A vaccine, and the seasonal influenza vaccine (the injected form).

Subunit, recombinant, and conjugate vaccines contain only specific pieces of the pathogen, such as a protein, polysaccharide, or sugar, rather than the whole organism. These vaccines are very safe because they cannot cause even a mild form of the disease, but they may require adjuvants (immune-stimulating substances) to enhance the immune response. Examples include the hepatitis B vaccine (which contains the viral surface antigen produced by recombinant DNA technology), the HPV vaccine, and the pneumococcal conjugate vaccine.

Toxoid vaccines are used against diseases caused by bacterial toxins rather than by the bacteria themselves. They contain inactivated toxins (toxoids) that have been chemically treated to eliminate their toxicity while preserving their ability to stimulate an immune response. The tetanus and diphtheria vaccines are toxoid vaccines that have been in use for decades with excellent safety records.

mRNA vaccines represent the newest vaccine technology, brought to global prominence by the Pfizer-BioNTech and Moderna COVID-19 vaccines. Instead of containing pathogen proteins or whole organisms, mRNA vaccines deliver genetic instructions that tell the body's own cells to produce a specific pathogen protein (such as the SARS-CoV-2 spike protein). The immune system then recognizes this protein as foreign and mounts an immune response. mRNA vaccines can be designed and manufactured rapidly, which was critical during the COVID-19 pandemic, and the platform is now being explored for vaccines against influenza, RSV, HIV, and certain cancers.

Viral vector vaccines use a harmless virus (the vector) to deliver genetic material from the target pathogen into cells, where it directs the production of pathogen proteins that stimulate an immune response. The Oxford-AstraZeneca and Johnson and Johnson COVID-19 vaccines used this approach, as does the approved Ebola vaccine (rVSV-ZEBOV).

Herd Immunity

When a sufficiently large proportion of a population is vaccinated against a disease, the pathogen cannot spread efficiently because it encounters too few susceptible individuals. This phenomenon, known as herd immunity (or community immunity), protects even those who cannot be vaccinated, such as newborns, immunocompromised individuals, and people with allergies to vaccine components. The vaccination threshold required for herd immunity varies by disease and depends on the basic reproduction number (R0), a measure of how many people one infected person typically infects in a fully susceptible population. Measles, with an R0 of 12 to 18, requires approximately 95% vaccination coverage for herd immunity. Polio and diphtheria require roughly 80 to 85%.

Vaccine Safety and Development

Vaccines undergo rigorous testing before approval. Development typically proceeds through preclinical studies (laboratory and animal testing), followed by three phases of clinical trials in humans. Phase I trials test safety in a small group of volunteers. Phase II trials assess immunogenicity (the ability to stimulate an immune response) and determine optimal dosing in a larger group. Phase III trials evaluate efficacy and safety in thousands to tens of thousands of participants, comparing vaccination against a placebo or existing vaccine. After approval, ongoing pharmacovigilance monitors for rare adverse events that may not have been detected in clinical trials.

No vaccine is 100% effective or completely free of side effects. Common side effects such as soreness at the injection site, mild fever, and fatigue reflect the normal activation of the immune system and typically resolve within a day or two. Serious adverse events are extremely rare and are carefully tracked by regulatory agencies and surveillance systems such as the Vaccine Adverse Event Reporting System (VAERS) in the United States. The benefits of vaccination, in terms of disease prevented, disability avoided, and lives saved, overwhelmingly outweigh the risks for the vast majority of individuals.

The Impact of Vaccination

Vaccination is widely regarded as one of the greatest public health achievements in history. The global eradication of smallpox in 1980, achieved through a systematic vaccination campaign coordinated by the World Health Organization, demonstrated that a human disease could be completely eliminated. Polio has been reduced by over 99% from its peak and remains endemic in only a handful of countries. Vaccines have dramatically reduced the global burden of measles, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b meningitis, and many other diseases. The Centers for Disease Control and Prevention has estimated that vaccines prevented over 21 million deaths and 732 million cases of disease among children born in the United States between 1994 and 2023.

Challenges in Vaccine Development

Despite the remarkable success of vaccination, effective vaccines have not yet been developed for many important infectious diseases. HIV, malaria, tuberculosis, and respiratory syncytial virus (RSV) have all proven extraordinarily difficult targets, though recent progress has been made on several fronts. The challenges vary by pathogen but often include high rates of antigenic variation (HIV mutates so rapidly that no fixed vaccine target remains stable), complex life cycles (malaria parasites pass through multiple developmental stages with different surface proteins), and the ability to evade or suppress immune responses.

The COVID-19 pandemic demonstrated both the potential and the limitations of modern vaccine technology. mRNA vaccines were designed and authorized for emergency use within less than a year of the virus's identification, a feat that would have been unimaginable with previous technologies. However, the rapid evolution of SARS-CoV-2 variants has required updated vaccine formulations, and achieving and maintaining high global vaccination coverage has proven challenging due to logistical, economic, and social barriers. Vaccine hesitancy, fueled by misinformation and distrust, has emerged as a significant obstacle to immunization programs worldwide, underscoring the importance of clear public health communication and community engagement.

Next-generation vaccine platforms, including self-amplifying RNA vaccines, nanoparticle vaccines, and universal vaccines designed to provide broad protection against all variants or even all members of a virus family (such as a universal influenza vaccine), are active areas of research that may overcome some of these challenges in the coming decades.